

Anti-IL-23 α (Tildrakizumab), Humanized Antibody

07/20

CATALOG NO.: A2159-100 (100 μ g)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a humanized IgG1 monoclonal antibody that specifically targets the p19 subunit of IL-23 and thereby inhibits the interaction with the IL-23 receptor. IL-23 is a cytokine that plays an important role in mediating inflammatory and immune responses. Binding of the antibody to IL-23 blocks the release of pro-inflammatory cytokines and chemokines associated with psoriasis. The original drug received approval from the FDA in 2018 to treat patients with moderate-to-severe plaque psoriasis who are candidates for systemic and phototherapy

ALTERNATE NAMES: MK-3222, SCH 900222, P19, SGRF, IL-23, IL23A, IL23P19

ANTIBODY TYPE: Monoclonal

CONCENTRATION: 1 mg/ml

HOST/ISOTYPE: Recombinant / IgG1, kappa

SOURCE: CHO cells

IMMUNOGEN: Human IL-23 α

CAS NUMBER: 1326244-10-3

MOLECULAR WEIGHT: 144.4 kDa

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80°C

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-IL-17R α (Brodalumab), Human IgG2 Antibody (A2155)

Anti-IL-23 α (Guselkumab), Human IgG1 Antibody (A2147)

Anti-IL-12 β (Ustekinumab), Human IgG1 Antibody (A2137)

Anti-TNF- α (Adalimumab), humanized Antibody (A1048)

Anti-IL-17 α (Secukinumab), Human IgG1 Antibody (A2154)

FOR RESEARCH USE ONLY! Not to be used on humans.